Welcome to Intelesens
Advances in medical technology, including wireless connectivity and wearable mobile devices are providing practitioners, medical centres, hospitals and telehealth service providers with important clinical tools to access and care for patients in new and innovative ways. Intelesens is at the forefront of this technology.
Our range of CE-approved and FDA cleared products, when combined with our zensoronline database and zensor+ software provides monitoring solutions that offer improved quality of care to patients, access to affordable care by those currently unmonitored and cost savings to healthcare providers.
Our products can:
- Provide clinicians with the opportunity to improve the speed of diagnosis and treatment of patients with cardiovascular and other acute and chronic diseases.
- Provide access to affordable health monitoring technology to hospital patients who are currently unmonitored and to chronically ill patients living in the community.
- Assist in reducing hospital stays by improving clinical outcomes in acute care and making it possible to monitor those recovering from hospitalisation or with chronic illnesses outside of the hospital environment.
Our portfolio of products, which have undergone a range of clinical trials to prove that they satisfy the current demand in innovative wireless technology whilst meeting with rigorous regulatory standards, include: V-Patch - a wireless, GPRS, Cardiac Arrhythmia Detection Device, Aingeal - our in-hospital wi-fi device which monitors respiration in addition to ECG, heart rate, skin temperature and motion and our latest device for home monitoring - zensor.
The Intelesens mission is to continue to provide innovative technologies and products which will improve the quality of care for ageing and ill populations. zensor launches in Q4 2014 and is a combined full disclosure and event monitor. zensor will monitor, collect, analyse and send heart rate, respiration rate, cardiac arrhythmias and motion data via wi-fi to a remote database. zensor allows faster analysis and diagnosis ensuring more responsive patient care. In response to the broader needs of the monitoring market we shall soon be including pulse oximetry to our existing range of vital signs parameters.
A university spin-out company, Intelesens maintains a dynamic collaborative relationship with world-class research teams in the Nanotechnology and Integrated BioEngineering Centre (NIBEC) based at the University of Ulster in Northern Ireland. Our products deliver real benefits for all healthcare professionals and their patients in a marketplace where there exists a rapidly growing demand and where wireless sensors and networks are estimated to reduce annual health costs by an estimated $25 billion per year.
Click here to download our white paper - Stroke Prevention: Atrial Fibrillation Screening.
Click here to download our latest brochure.